Issue of Equity and Total Voting Rights

SkinBioTherapeutics PLC

20 January 2026

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Issue of Equity and Total Voting Rights

20 January 2026 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it has issued, conditional on admission, 129,736 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the share options agreement entered into by the Company and a previous employee upon IPO.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue and application has been made for the new Ordinary Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission is expected to occur, and dealings in the new Ordinary Shares commence, at 8:00 a.m. on 22 January 2026.

Total Voting Rights

Following Admission, the Company will have 258,779,463 Ordinary Shares in issue. This figure of 258,779,463 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-   

For more information please contact:

SkinBioTherapeutics plc Stuart J. Ashman, CEO Emily Bertram, CFO	[phone]
Singer Capital Markets (Nominated Adviser & Broker) Philip Davies James Todd Patrick Weaver	[phone]
Vigo Consulting (financial press) Melanie Toyne-Sewell Rozi Morris	[phone] [e-mail]

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix^®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix^® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

 

END